Through hierarchically targeting bone matrix and tumor cells, PTX-carrying ALN/FA-nanoparticles substantially accumulate in bone metastases and improve mice survival rate.

Background: This study aims to compare the effectiveness of inhaled prostacyclin or its analoguesversus nitric oxide (NO) in treating pulmonary hypertension (PH) after cardiac or pulmonary surgery remains unclear. Methods: PubMed, Cochrane, and Embase databases were searched for literature published prior to December 2019 using the following keywords: inhaled, nitric oxide, prostacyclin, iloprost, treprostinil, epoprostenol, Tyvaso, flolan, and pulmonary hypertension. Randomized controlled trials and multiple-armed prospective studies that evaluated inhaled NO versus prostacyclin (or analogues) in patients for perioperative and/or postoperative PH after either cardiac or pulmonary surgery were included. Retrospective studies, reviews, letters, comments, editorials, and case reports were excluded. Results: Seven studies with a total of 195 patients were included. No difference in the improvement of mean pulmonary arterial pressure (pooled difference in mean change¼ À0.10, 95% CI: À3.98 to 3.78, p ¼ .959) or pulmonary vascular resistance (pooled standardized difference in mean change¼ À0.27, 95% CI: À0.60 to 0.05, p ¼ .099) were found between the two treatments. Similarly, no difference was found in other outcomes between the two treatments or subgroup analysis. Conclusions: Inhaled prostacyclin (or analogues) was comparable to inhaled NO in treating PH after cardiac or pulmonary surgery. KEY MESSAGESThis study compared the efficacy of inhaled prostacyclin or its analogues versus inhaled NO to treat PH after surgery. The two types of agent exhibited similar efficacy in managing MPAP, PVR, heart rate, and cardiac output was observed. Inhaled prostacyclin may serve as an alternative treatment option for PH after cardiac or pulmonary surgery.

Supplemental Digital Content is available in the text